Diagnostic Utility of Claudin-4 Immunohistochemistry in Distinguishing Adenocarcinoma Cells from Reactive Mesothelial Cells in Effusion Cytology

Authors

  • Mihira Ginnavaram Department of Pathology, Nizam’s Institute of Medical Sciences, Hyderabad
  • Pramod Kumar Pamu Department of Pathology, Prathima Institute of Medical Sciences (PIMS), Karimnagar
  • Swetha Kesarapu Department of Medical Oncology, Nizam’s Institute Of Medical Sciences, Hyderabad
  • Narayanan Ramakrishna Department of Radiology, Nizam’s Institute Of Medical Sciences, Hyderabad

DOI:

https://doi.org/10.15850/ijihs.v13n2.4561

Keywords:

Adenocarcinoma, claudin-4, effusion cytology, immunohistochemistry, mesothelial cells

Abstract

Background: Differentiating adenocarcinoma cells from reactive mesothelial cells in cases of effusion remains a diagnostic challenge due to overlapping morphological features. Claudin-4, a tight junction protein expressed in epithelial but absent in mesothelial cells, has emerged as a potential immunohistochemical (IHC) marker for this distinguishing between these cell types.

Objective: to evaluate the diagnostic utility of Claudin-4 immunohistochemistry in differentiating adenocarcinoma cells from reactive mesothelial cells in effusion cytology.

Methods: This prospective study was conducted at the Department of Pathology, Nizam’s Institute of Medical Sciences, Hyderabad, India, between June 2023 and December 2024. A total of 77 formalin-fixed paraffin-embedded cell block samples from effusion fluids (pleural, ascitic, and peritoneal) were analyzed. Inclusion criteria comprised cases diagnosed as malignant or reactive on cytology. Claudin-4 immunostaining was performed by using  EP417 clone. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of Claudine for differentiating malignant versus non-malignant effusion was calculated.

Results: Out of the 77 studied cases, 57 were malignant and 20 were non-malignant. Claudin-4 showed positive membranous staining in 50/57 malignant cases (87.72%) and in none of the non-malignant cases (100% specificity). The PPV was 100%, and NPV was 74.10%. Pulmonary adenocarcinoma was the most common malignancy showing Claudin-4 positivity. Claudin demonstrated excellent specificity for diagnosis of malignant effusions. 

Conclusion: Claudin-4 immunohistochemistry is highly specific as a reliable marker for differentiating malignant cells from reactive mesothelial cells. Its high specificity and positive predictive value make it a valuable diagnostic tool. However, a negative Claudin-4 immunohistochemistry results should be interpreted cautiously, particularly in clinically suspicious cases.

References

  1. Halimi M, Beheshti-Rouy S, Salehi D, Rasihashemi SZ. The role of immunohistochemistry studies in distinguishing malignant mesothelioma from metastatic lung carcinoma in malignant pleural effusion. Iran J Pathol. 2019;14(2):122–6. doi:10.30699/ijp.14.2.122
  2. Pereira TC, Saad RS, Liu Y, Silverman JF. The diagnosis of malignancy in effusion cytology: a pattern recognition approach. Adv Anat Pathol. 2006;13(4):174-84. doi:10.1097/00125480-200607000-00004
  3. Fujiwara-Tani R, Mori S, Ogata R, Sasaki R, Ikemoto A, Kishi S, et al. Claudin-4: a new molecular target for epithelial cancer therapy. Int J Mol Sci. 2023;24(6):5494. doi:10.3390/ijms24065494
  4. Dithmer S, Blasig IE, Fraser PA, Qin Z, Haseloff RF. The basic requirement of tight junction proteins in blood-brain barrier function and their role in pathologies. Int J Mol Sci. 2024;25(11):5601. doi:10.3390/ijms25115601
  5. Monaco S, Mehrad M, Dacic S. Recent advances in the diagnosis of malignant mesothelioma: focus on approach in challenging cases and in limited tissue and cytologic samples. Adv Anat Pathol. 2018;25(1):24-30. doi:10.1097/pap.0000000000000176
  6. Jo VY, Cibas ES, Pinkus GS. Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology. Cancer Cytopathol. 2014;122(4):299-306. doi:10.1002/cncy.21392
  7. Soini Y, Kinnula V, Kahlos K, Pääkkö P. Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura. J Clin Pathol. 2006;59(3):250-4. doi:10.1136/jcp.2005.028589
  8. Patel A, Borczuk AC, Siddiqui MT. Utility of claudin-4 versus BerEP4 and B72.3 in pleural fluids with metastatic lung adenocarcinoma. J Am Soc Cytopathol. 2020;9(3):146-51. doi:10.1016/j.jasc.2019.12.003
  9. Kleinaki M, Vey JA, Awounvo S, Ishak A, Arnaouti M, Ryu HS, et al. The diagnostic accuracy of claudin-4 immunochemistry in differentiating metastatic carcinomas from mesothelial processes in serous effusion cytology: a systematic review and meta-analysis. Arch Pathol Lab Med. 2025;149(4):381-8. doi:10.5858/arpa.2023-0560-RA
  10. Najjar S, Gan Q, Stewart J, Sneige N. The utility of claudin-4 versus MOC-31 and Ber-EP4 in the diagnosis of metastatic carcinoma in cytology specimens. Cancer Cytopathol. 2023;131(4):245-53. doi:10.1002/cncy.22672
  11. Elhosainy A, Hafez MMA, Yassin EH, Adam M, Elnaggar MS, Aboulhagag NA. Diagnostic value of claudin-4 and EZH2 immunohistochemistry in effusion cytology. Asian Pac J Cancer Prev. 2022;23(8):2779-85. doi:10.31557/apjcp.2022.23.8.2779
  12. Afshar-Moghaddam N, Heidarpour M, Dashti S. Diagnostic value of claudin-4 marker in pleural and peritoneal effusion cytology: does it differentiate between metastatic adenocarcinoma and reactive mesothelial cells? Adv Biomed Res. 2014;3:161. doi:10.4103/2277-9175.138888
  13. Tessier-Cloutier B, Soslow RA, Stewart CJR, Köbel M, Lee CH. Frequent loss of claudin-4 expression in dedifferentiated and undifferentiated endometrial carcinomas. Histopathology. 2018;73(2):299-305. doi:10.1111/his.13525
  14. Naso JR, Churg A. Claudin-4 shows superior specificity for mesothelioma vs non-small-cell lung carcinoma compared with MOC-31 and Ber-EP4. Hum Pathol. 2020;100:10-4. doi:10.1016/j.humpath.2020.04.005
  15. Haque M, Kaur H, Wang M, Cai G. Comparative assessment of claudin-4, MOC-31, and BerEP4 immunomarkers in diagnostic workup of metastatic carcinoma in serous fluid specimens. Lab Invest. 2025;105(3):341-52. doi:10.1016/j.labinv.2024.102568

Downloads

Published

2025-10-30

Issue

Vol. 13 No. 2 (2025)

Section

Articles

License

Authors retain copyright and grant International Journal of Integrated Health Sciences right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to freely share and remix the work with an acknowledgement of the work's authorship and initial publication in International Journal of Integrated Health Sciences.